Verily, Google’s health tech spinout, is set to make another pivot in the coming year and a half as it transitions from its chronic disease management app Onduo to a new product called Lightpath. While Onduo will be phased out, Lightpath Metabolic is expected to launch in 2026 and will offer GLP-1 drug prescriptions, personalized care through artificial intelligence and data from devices like continuous glucose monitoring devices.
Despite this shift in focus, Verily’s move towards an app that offers AI assistance and telehealth prescriptions marks a departure from its original vision of “defeating Mother Nature.” The company has faced challenges in finding its direction over the last nine years. Projects like a contact-lens continuous glucose monitor have been abandoned, and turnover among employees and executives has been a recurring issue for the company.
Nevertheless, with the introduction of Lightpath Metabolic, Verily continues to evolve its offerings to meet the changing needs of users in the healthcare space. For more in-depth analysis of the technologies disrupting healthcare, readers can access exclusive content on STAT+ by subscribing for unlimited access to award-winning journalism and exclusive events.
